Booster Immunization with a Fractional Dose of Prevnar 13 Affects Cell-mediated Immune Response but Not Humoral Immunity in CD-1 Mice

Overview

Journal Heliyon

Specialty Social Sciences

Date 2021 Jul 1

PMID 34195422

Authors

Rose-Marie Catalioto

Claudio Valenti

Francesca Bellucci

Cecilia Cialdai

Maria Altamura

Laura Digilio

Andrea Ugo Enrico Pellacani

Stefania Meini

Affiliations

Soon will be listed here.

Abstract

Achieving durable protective immunity following vaccination is dependent on many factors, including vaccine composition and antigen dose, and it has been investigated for various types of vaccines. Aim of the present study was to investigate the overall immune response elicited by two different booster doses in CD-1 mice, by exploiting the largely used 13-valent pneumococcal conjugate vaccine Prevnar 13® (PCV13). Immunization was performed by two primary doses of PCV13 two weeks apart, and a full or fractional (1/5) booster dose on week 10. Serotype-specific antibody titer, avidity, and opsonophagocytic activity were evaluated one week later, and compared to cell-mediated immunity (CMI) responses determined as the frequency of cytokines producing splenocytes by recall with the antigens (carrier protein and polysaccharides). Data showed that regardless of the booster dose, a comparable humoral response was produced, characterized by similar amounts of serotype-specific antibodies, with analog avidity and opsonophagocytic properties. On the other hand, when CMI was evaluated, the presence of CRM197-specific IL-5 and IL-2 producing cells was evident in splenocytes from mice immunized with the full dose, while in those immunized with the fractional booster dose, IFN-γ producing cells responsive to both protein and polysaccharide antigens were significantly increased, whereas the number of IL-5 and IL-2 positive cells remained unaffected. Overall the present findings show that PCV13 humoral response in mice is associated to a Th2 predominant response at the full booster dose, while the fractional one favors a mixed Th1/Th2 response, suggesting an important role of CMI besides measurement of functional protective antibodies, as an additional and important key information in vaccine development.

References

Cousins D, Lee T, Staynov D . Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence for coordinated expression of Th2 cytokines. J Immunol. 2002; 169(5):2498-506. DOI: 10.4049/jimmunol.169.5.2498. View

Wernette C, Frasch C, Madore D, Carlone G, Goldblatt D, Plikaytis B . Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003; 10(4):514-9. PMC: 164258. DOI: 10.1128/cdli.10.4.514-519.2003. View

Milucky J, Carvalho M, Rouphael N, Bennett N, Talbot H, Harrison L . Streptococcus pneumoniae colonization after introduction of 13-valent pneumococcal conjugate vaccine for US adults 65 years of age and older, 2015-2016. Vaccine. 2019; 37(8):1094-1100. PMC: 6371770. DOI: 10.1016/j.vaccine.2018.12.075. View

Caro-Aguilar I, Indrawati L, Kaufhold R, Gaunt C, Zhang Y, Nawrocki D . Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain. Vaccine. 2017; 35(6):865-872. DOI: 10.1016/j.vaccine.2016.12.055. View

Loo J, Conklin L, Fleming-Dutra K, Knoll M, Park D, Kirk J . Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J. 2013; 33 Suppl 2:S140-51. PMC: 3944478. DOI: 10.1097/INF.0000000000000082. View

Jakobsen H, Saeland E, Gizurarson S, Schulz D, Jonsdottir I . Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections. Infect Immun. 1999; 67(8):4128-33. PMC: 96716. DOI: 10.1128/IAI.67.8.4128-4133.1999. View

. Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine. 2012; 30(32):4717-8. DOI: 10.1016/j.vaccine.2012.04.093. View

Sucher A, Chahine E, Nelson M, Sucher B . Prevnar 13, the new 13-valent pneumococcal conjugate vaccine. Ann Pharmacother. 2011; 45(12):1516-24. DOI: 10.1345/aph.1Q347. View

Polonskaya Z, Deng S, Sarkar A, Kain L, Comellas-Aragones M, McKay C . T cells control the generation of nanomolar-affinity anti-glycan antibodies. J Clin Invest. 2017; 127(4):1491-1504. PMC: 5373877. DOI: 10.1172/JCI91192. View

10.

Zanetti M, Franchini G . T cell memory and protective immunity by vaccination: is more better?. Trends Immunol. 2006; 27(11):511-7. DOI: 10.1016/j.it.2006.09.004. View

11.

Sallusto F, Lanzavecchia A, Araki K, Ahmed R . From vaccines to memory and back. Immunity. 2010; 33(4):451-63. PMC: 3760154. DOI: 10.1016/j.immuni.2010.10.008. View

12.

Mawas F, Feavers I, Corbel M . Serotype of Streptococcus pneumoniae capsular polysaccharide can modify the Th1/Th2 cytokine profile and IgG subclass response to pneumococal-CRM(197) conjugate vaccines in a murine model. Vaccine. 2001; 19(9-10):1159-66. DOI: 10.1016/s0264-410x(00)00314-5. View

13.

Romero-Steiner S, Musher D, Cetron M, Pais L, Groover J, Fiore A . Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 1999; 29(2):281-8. DOI: 10.1086/520200. View

14.

Jensen K, Melchjorsen J, Dagnaes-Hansen F, Sorensen U, Laursen R, Ostergaard L . Timing of Toll-like receptor 9 agonist administration in pneumococcal vaccination impacts both humoral and cellular immune responses as well as nasopharyngeal colonization in mice. Infect Immun. 2012; 80(5):1744-52. PMC: 3347424. DOI: 10.1128/IAI.00079-12. View

15.

Regules J, Cicatelli S, Bennett J, Paolino K, Twomey P, Moon J . Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. J Infect Dis. 2016; 214(5):762-71. DOI: 10.1093/infdis/jiw237. View

16.

Aagaard C, Hoang T, Izzo A, Billeskov R, Troudt J, Arnett K . Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One. 2009; 4(6):e5930. PMC: 2691953. DOI: 10.1371/journal.pone.0005930. View

17.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

18.

Michon F, Fusco P, Minetti C, Uitz C, Huang C, DAmbra A . Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein. Vaccine. 1998; 16(18):1732-41. DOI: 10.1016/s0264-410x(98)00225-4. View

19.

Lai Z, Schreiber J . Outer membrane protein complex of Meningococcus enhances the antipolysaccharide antibody response to pneumococcal polysaccharide-CRM₁₉₇ conjugate vaccine. Clin Vaccine Immunol. 2011; 18(5):724-9. PMC: 3122513. DOI: 10.1128/CVI.00053-11. View

20.

Anttila M, Eskola J, Ahman H, Kayhty H . Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis. 1998; 177(6):1614-21. DOI: 10.1086/515298. View